Oxurion NV (EBR:OXUR)
Belgium · Delayed Price · Currency is EUR 0.0156
+0.0004 (2.63%)
Oct 22, 2025, 5:27 PM CET
Oxurion NV Revenue
Oxurion NV had revenue of 2.00K EUR in the twelve months ending June 30, 2025, down -97.62% year-over-year. In the year 2024, Oxurion NV had annual revenue of 3.00K, down -98.86%.
Revenue (ttm)
2.00K
Revenue Growth
-97.62%
P/S Ratio
382.87
Revenue / Employee
181.82
Employees
11
Market Cap
765.74K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.00K | -260.00K | -98.86% |
| Dec 31, 2023 | 263.00K | -332.00K | -55.80% |
| Dec 31, 2022 | 595.00K | -533.00K | -47.25% |
| Dec 31, 2021 | 1.13M | -950.00K | -45.72% |
| Dec 31, 2020 | 2.08M | -1.87M | -47.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| argenx SE | 2.66B |
| Fagron NV | 918.75M |
| Ion Beam Applications | 585.76M |
| European Medical Solutions | 49.47M |
| Biocartis Group NV | 47.69M |
| Hyloris Pharmaceuticals | 8.46M |
| Nyxoah | 4.93M |